Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
Phase I / IIa Clinical Trial for Patients With Hepatitis C or B Virus Derived Liver Cirrhosis by CBP / β Catenin Inhibitor PRI-724
Sponsor: Japan Agency for Medical Research and Development
Listed as NCT03620474, this PHASE1/PHASE2 trial focuses on Hepatitis B and Hepatitis C and remains completed. Sponsored by Japan Agency for Medical Research and Development, it has been updated 12 times since 2018, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Agency for Medical Research and Development
- Kiminori Kimura, MD
- Kyushu University
- National Center for Global Health and Medicine, Japan
- Ohara Pharmaceutical Co., Ltd.
- Prism Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .